These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34969998)

  • 1. The multi-specific V
    Edwards CJ; Sette A; Cox C; Di Fiore B; Wyre C; Sydoruk D; Yadin D; Hayes P; Stelter S; Bartlett PD; Zuazo M; Garcia-Granda MJ; Benedetti G; Fiaska S; Birkett NR; Teng Y; Enever C; Arasanz H; Bocanegra A; Chocarro L; Fernandez G; Vera R; Archer B; Osuch I; Lewandowska M; Surani YM; Kochan G; Escors D; Legg J; Pierce AJ
    Br J Cancer; 2022 May; 126(8):1168-1177. PubMed ID: 34969998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.
    Huang RY; Eppolito C; Lele S; Shrikant P; Matsuzaki J; Odunsi K
    Oncotarget; 2015 Sep; 6(29):27359-77. PubMed ID: 26318293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction.
    Bhagwat B; Cherwinski H; Sathe M; Seghezzi W; McClanahan TK; de Waal Malefyt R; Willingham A
    J Immunol Methods; 2018 May; 456():7-14. PubMed ID: 29427592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
    Liu Y; Guo X; Zhan L; Wang L; Wang X; Jiang M
    Comput Math Methods Med; 2021; 2021():4468140. PubMed ID: 34422089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAG3 (CD223) as a cancer immunotherapy target.
    Andrews LP; Marciscano AE; Drake CG; Vignali DA
    Immunol Rev; 2017 Mar; 276(1):80-96. PubMed ID: 28258692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.
    Zhang Q; Salzler R; Dore A; Yang J; Ma D; Olson WC; Liu Y
    J Proteome Res; 2018 Nov; 17(11):3932-3940. PubMed ID: 30277784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy.
    Du H; Yi Z; Wang L; Li Z; Niu B; Ren G
    Int Immunopharmacol; 2020 Jan; 78():106113. PubMed ID: 31841754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
    Natoli M; Hatje K; Gulati P; Junker F; Herzig P; Jiang Z; Davydov II; Germann M; Trüb M; Marbach D; Zwick A; Weber P; Seeber S; Wiese M; Lardinois D; Heinzelmann-Schwarz V; Rosenberg R; Tietze L; Mertz KD; Umaña P; Klein C; Codarri-Deak L; Kao H; Zippelius A
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
    Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
    Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Function and regulation of LAG3 on CD4
    Ma QY; Huang DY; Zhang HJ; Wang S; Chen XF
    Exp Cell Res; 2017 Nov; 360(2):358-364. PubMed ID: 28935468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
    Andrews LP; Somasundaram A; Moskovitz JM; Szymczak-Workman AL; Liu C; Cillo AR; Lin H; Normolle DP; Moynihan KD; Taniuchi I; Irvine DJ; Kirkwood JM; Lipson EJ; Ferris RL; Bruno TC; Workman CJ; Vignali DAA
    Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.
    Andrews LP; Cillo AR; Karapetyan L; Kirkwood JM; Workman CJ; Vignali DAA
    Clin Cancer Res; 2022 Dec; 28(23):5030-5039. PubMed ID: 35579997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
    Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
    Front Immunol; 2021; 12():648420. PubMed ID: 34589081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
    Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
    Front Immunol; 2020; 11():563258. PubMed ID: 33488573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 18. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
    Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
    MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
    Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
    Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.
    Kim AK; Gani F; Layman AJ; Besharati S; Zhu Q; Succaria F; Engle EL; Bhaijee F; Goggins MB; Llosa NJ; Pawlik TM; Yarchoan M; Jaffee EM; Simons HC; Taube JM; Anders RA
    Cancer Immunol Res; 2019 May; 7(5):805-812. PubMed ID: 30902819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.